

Contents

1	Peritoneal Dissemination of Gastrointestinal Tumors	1
1.1	Peritoneal Carcinomatosis from Colorectal Cancer.....	1
1.1.1	Incidence and Natural History	1
1.1.2	Pathogenesis.....	2
1.1.3	Predicting and Predisposing Factors	4
1.1.4	Diagnostic and Prognostic Evaluation	5
1.1.5	Treatment	8
1.2	Peritoneal Carcinomatosis from Gastric Cancer.....	17
1.2.1	Incidence and Natural History	17
1.2.2	Pathogenesis.....	18
1.2.3	Risk Factors	20
1.2.4	Diagnostic Evaluation.....	20
1.2.5	Staging and Prognostic Tools.....	21
1.2.6	Treatment	23
1.3	Pseudomyxoma Peritonei.....	30
1.3.1	Incidence and Natural History	30
1.3.2	Definition and Etiology.....	31
1.3.3	Nomenclature and Classification	31
1.3.4	Pathogenesis.....	32
1.3.5	Clinical Presentation	33
1.3.6	Diagnosis.....	34
1.3.7	Treatment	36
2	Mucins and Tumor Biology	43
2.1	Classification.....	43
2.2	Molecular Structure	45
2.3	Membrane-Associated Mucins	47
2.3.1	MUC1	48
2.4	Secreted Mucins.....	50
2.4.1	MUC2	51
2.4.2	MUC5AC.....	52

2.5	Regulation of Mucin Expression	52
2.5.1	Regulation of MUC1 Expression.....	53
2.5.2	Regulation of MUC2 and MUC5AC Expression.....	53
2.6	Mucins in Health and Cancer.....	55
2.6.1	Mucins and Gastrointestinal Physiology	55
2.6.2	Mucins in Cancer	57
3	Bromelain.....	63
3.1	History.....	63
3.2	Manufacturing Process Summary	64
3.3	Biochemical Properties	65
3.4	Pharmacokinetics	66
3.5	Pharmacodynamics	67
3.5.1	Anti-inflammatory Effects	68
3.5.2	Immunomodulatory Effects	68
3.5.3	Antithrombotic and Fibrinolytic Activities.....	69
3.5.4	Protection Against Ischemia-Reperfusion Injury.....	69
3.5.5	Protective Effects on Gastrointestinal Physiology	69
3.5.6	Potential of Antibiotics Absorption	70
3.5.7	Effects on Malignant Growth.....	70
3.6	Potential and Actual Applications	76
3.6.1	Gastrointestinal Health and Disease	76
3.6.2	Infections.....	76
3.6.3	Inflammatory Diseases.....	77
3.6.4	Musculoskeletal Injuries	77
3.6.5	Surgical Trauma.....	78
3.6.6	Thrombotic and Ischemic Disorders.....	78
3.6.7	Burn Debridement.....	78
3.6.8	Cancer	79
3.7	Safety and Tolerability.....	79
3.7.1	Acute Toxicology.....	79
3.7.2	Chronic Toxicology.....	80
3.7.3	Side Effects	80
4	N-Acetylcysteine.....	81
4.1	History.....	81
4.2	Manufacturing Process Summary	82
4.3	Biochemical Properties	82
4.4	Pharmacokinetics	83
4.5	Pharmacodynamics	83
4.5.1	Antioxidant activity.....	84
4.5.2	Protein Modification	85
4.5.3	Detoxification and Chelation	85
4.5.4	Regulatory Effects on Cell Biology	86
4.5.5	Immunomodulation.....	90
4.5.6	Effects on Malignant Growth.....	91

- 4.6 Potential and Actual Applications 92
 - 4.6.1 Respiratory Diseases 92
 - 4.6.2 Poisoning..... 93
 - 4.6.3 Contrast-Induced Nephropathy 93
 - 4.6.4 Circulatory Diseases 94
 - 4.6.5 Viral Infections..... 94
 - 4.6.6 Neuropsychiatric Disorders 95
 - 4.6.7 Other Potential Applications..... 96
- 4.7 Safety and Tolerability 97
 - 4.7.1 Acute Toxicology 97
 - 4.7.2 Subacute and Chronic Toxicology 97
 - 4.7.3 Side Effects 97
- 5 A Novel Approach to Peritoneal Dissemination
of Mucin-Expressing Malignancies of Gastrointestinal Origin 99**
 - 5.1 Cytotoxic Effects of Bromelain and N-acetylcysteine
in Single Agent and Combination Treatment
of Human Gastrointestinal Carcinoma Cell Lines, In Vitro 99
 - 5.1.1 Introduction..... 99
 - 5.1.2 Results..... 100
 - 5.1.3 Discussion..... 103
 - 5.2 Effects of BR/NAC on Chemosensitivity
of Gastrointestinal Cancer Cells in Sequential
and Combination Therapy In Vitro 112
 - 5.2.1 Introduction..... 112
 - 5.2.2 Results..... 112
 - 5.2.3 Discussion..... 116
 - 5.3 Mucin-Depleting Effects of BR/NAC on Mucin-Expressing
Gastrointestinal Carcinoma Cells 121
 - 5.3.1 Introduction..... 121
 - 5.3.2 Results..... 122
 - 5.3.3 Discussion..... 126
 - 5.4 Efficacy of Intraperitoneal Administration of BR/NAC
in Two Animal Models of Peritoneal Dissemination
of Human Gastric and Colon Carcinoma..... 138
 - 5.4.1 Introduction..... 138
 - 5.4.2 Results..... 140
 - 5.4.3 Discussion..... 146
- 6 Summary and Future Directions 159**
 - 6.1 Summary of the Study 159
 - 6.2 Future Directions 163
- References 165**
- Index..... 225**